PLENARY LECTURE: Modeling cancer in the mouse
Tyler Jacks, PhD
Director, Koch Institute for Integrative Cancer Research
Tyler Jacks, PhD is the Director of the Koch Institute for Integrative Cancer Research at MIT, the David H. Koch Professor of Biology and an Investigator of the Howard Hughes Medical Institute. Over the course of his career at MIT, Dr. Jacks has pioneered the use of gene targeting technology to study cancer-associated genes and to construct models of many human cancer types, including cancers of the lung, brain and ovary. His laboratory has made seminal contributions to the understanding of the effects of mutations of several common cancer-associated genes. This research has led to novel insights into tumor development, normal development and other cellular processes, as well as new strategies for cancer detection and treatment. Dr. Jacks has published more than 200 scientific papers.

Dr. Jacks has served on the Board of Scientific Advisors of the National Cancer Institute, is the immediate past chair of the National Cancer Advisory Board, and served as co-chair of Vice President Biden’s Cancer Moonshot’s Blue Ribbon Panel. He is an advisor to several biotechnology and pharmaceutical companies, and is a director of Amgen and Thermo Fisher Scientific. Among many honors, Dr. Jacks is a member of the National Academy of Sciences, the Institute of Medicine of the National Academies, the American Academy of Arts and Sciences, and the Fellows of the American Association of Cancer Research Academy.


SYMPOSIUM 1: Radiation-induced GI Syndrome
Jian Yu, PhD
University of Pittsburgh Medical Center
Marimar de la Cruz Bonilla, B. Sc
MD Anderson Cancer Center   
Steven Zhang
University of Florida, DVM, PhD    
Cullen Taniguchi MD, PhD
MD Anderson Cancer Center
 Payel Bhanja, PhD
 Kansas University Medical Center   
SYMPOSIUM 2: Radiation dosimetry: In patients and phantoms
 Brian Pogue, PhD
Thayer School of Engineering
at Dartmouth
 Yaser Gholami, PhD
   The University of Sydney 
Mihaela Ghita, PhD
Queen's University Belfast 
 Chiara La Tessa, PhD
University of Trento
 Claude Rogers
SYMPOSIUM 3: Mechanisms of cell death after radiation
Kristopher Sarosiek, PhD
Harvard T.H. Chan School of Public Health
Kishore Kumar Jella, PhD, MS
   Emory University School of Medicine
Stephanie Markovina, MD, PhD
Washington University in St. Louis School of Medicine    
Daohong Zhou, MD 
University of Arkansas for Medical Science
Marc Mendonca, PhD
Indiana University School of Medicine
SYMPOSIUM 4: Hypofractionation: from pre-clinical models to clinical trials
Tadashi Kamada, MD, PhD
National Institute of Radiological Sciences
 Navita Somaiah, MD, PhD
The Institute of Cancer Research, London
 Albert van der Kogel, PhD
University of Wisconsin School of Medicine
 Theodore (Ted) Hong, MD
Massachusetts General Hospital
SYMPOSIUM 5: Genomics of normal tissue toxicity and tumor response to radiation
Mohamed Abazeed MD, PhD 
Cleveland Clinic
Warren Robert Floyd, BS
Duke MSTP- Molecular Cancer Biology    
Rachel Andrews, PhD
   Wake Forest University 
 Kent Mouw MD, PhD 
Dana-Farber Cancer Institute
Rachel Schlaak, BS
Medical College of Wisconsin     
SYMPOSIUM 6: Hypoxia and ER stress

Constantinos Koumenis, PhD
University of Pennsylvania
Cameron Koch, MD
   University of Pennsylvania 
 William Wilson, PhD
Auckland Cancer Soc Research Center    
 Marianne Koritzinsky, PhD
University Health Network
Charles Maitz, PhD 
University of Missouri  
SYMPOSIUM 7: Imaging and circulating biomarkers of radiation response
Max Diehn MD, PhD
Stanford Medicine
Eunjoo Chung, PhD
Andrew Wang, MD 
University of North Carolina
School of Medicine
 John Floberg, PhD
    Washington University in St. Louis School of Medicine    
SYMPOSIUM 8: Radionuclides for imaging, therapy, and dosimetry
David Mankoff MD, PhD
University of Pennsylvania
Robert Hobbs, PhD
Johns Hopkins University School of Medicine 
Ana Ponce Kiess MD, PhD 
Johns Hopkins Medicine
 Rebecca Abergel, PhD
Lawrence Berkeley Laboratory
SYMPOSIUM 9: Chromatin biology and radiation response
Brendan Price, PhD
Dana-Farber Cancer Institute
Anthony Davis, PhD
   Univ of Texas SW Medical Center 
Julio Morales, PhD 
   University of Oklahoma HSC 
Tej Pandita, PhD
Houston Methodist 
Katherine Castle, PhD
Duke University Medical Center     
SYMPOSIUM 10: Joint Session (CRH)Space radiation and cancer risk
 Mike Weil, PhD
Colorado State University
Shubhankar Suman, PhD
Georgetown University 

Audrey Hu, PhD
Fred Hutchinson Cancer Center
Sylvain Costes, PhD
NASA Ames Research Center 

 Zarana Patel, PhD
NASA Johnson Space Center / USRA     

FAILLA LECTURE: Adaciu Adaciu si fa Gran Viaggiu: With a heavy ion accelerator you can travel to mars

Francis A. Cucinotta, PhD
Dr. Francis A. Cucinotta is a Professor of Health Physics at the University of Nevada, Las Vegas. Dr. Cucinotta received his Doctorate degree in nuclear physics from Old Dominion University in 1988. He worked at NASA Johnson Space Center from 1997-2013 as the Radiological Health Officer, Space Radiation Project Manager and Chief Scientist. He developed the astronaut exposure data base of organ doses and cancer risk estimates for all human missions from Mercury to the International Space Station (ISS). He was NASA’s manager for construction and operations of the NASA Space Radiation Laboratory (NSRL) from 1999-2013. Dr. Cucinotta worked on radiation safety in NASA’s Mission Control Center for the Space Shuttle and ISS programs in 1989-1990, and 2000-2006. He has published over 350 peer-reviewed journal articles in a broad range of topical areas, including nuclear and space physics, track structure, biophysics models of DNA damage repair and neuronal effects, biodosimetry, radiation cataracts, and risk assessment models for cancer and acute health effects. Dr. Cucinotta is a past President of the Radiation Research Society (2013-2014), and a Council Member of the National Council of Radiation Protection and Measurements (NCRP).

James DeGregori, PhD
University of Colorado Denver
School of Medicine
Amitava Adhikary, PhD
Oakland University
Joseph Deasy, PhD
Memorial Sloan Kettering Cancer Center
Marjan Boerma, PhD
University of Arkansas for
Medical Science
Scott Floyd MD, PhD 
Duke University School of Medicine
PLENARY LECTURE: Cancer etiology and its mutational signatures
Assistant Professor, Johns Hopkins University
Dr. Cristian Tomasetti is an Associate Professor in the Division of Biostatistics and Bioinformatics of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, and in the Department of Biostatistics of the Johns Hopkins Bloomberg School of Public Health.
His work is recognized internationally for his paradigm-shift contributions to the current understanding of cancer etiology and tumor evolution. He is also actively working on the development of novel methodologies for the estimation of cancer risk, as well as on the development of algorithms for the early detection of cancer via screening.
Dr. Tomasetti earned a Ph.D. in Applied Mathematics from the University of Maryland, College Park (Dec. 2010). He was then a Ruth L. Kirschstein National Research Service Award Postdoctoral Fellow in the Department of Biostatistics of the Harvard School of Public Health and in the Department of Biostatistics and Computational Biology of the Dana-Farber Cancer Institute (Jan 2011 – Jun 2013). Since then he has been a faculty member at Hopkins.

SYMPOSIUM 11: Pre-clinical mechanisms of radiation and immunotherapy
Andy Minn MD, PhD
University of Pennsylvania
Ravi Patel, PhD
 University of Wisconsin - Madison   
Riddhi Falk-Mahapatra, MS
Roswell Park Cancer Inst    
Elizabeth Repasky, PhD 
Roswell Park Comprehensive Cancer Center 
Amy Wisdom, BS
   Duke University School of Medicine 
SYMPOSIUM 12: Dose rate and radiation toxicity
Marie-Catherine Vozenin, PhD
Peter Maxim, PhD 
Stanford University Medical Center   
G-One Ahn, PhD
Pohang University of Science and Technology
Andre Paredes, B. Sc
University of Illinois at Chicago 
SYMPOSIUM 13: A tribute and celebration: the contributions and impact of Michael Fry to Radiation Research
Eleanor Blakely, PhD
Lawrence Berkeley National Laboratory
Amy Kronenberg, ScD
Lawrence Berkeley National Laboratory
John Boice, ScD
Vanderbilt-Ingram Cancer Center
Robert Ullrich, MD
University of Texas Medical Branch 
SYMPOSIUM 14: Reactive oxygen species, redox and metabolism
Julie Schwarz MD, PhD
Washington University School of Medicine
Afshin Beheshti, PhD
   NASA Ames Research Center 
Kushal Kadakia
 Duke University   
 Alec Kimmelman MD, PhD
NYU Langone Health
Anqi Yao, Msc
University of Nottingham     
SYMPOSIUM 15: Track structure and Monte Carlo modeling of biological effects
José Ramos-Méndez, PhD
University of California- San Francisco
 Congchong Yan, PhD
UT Southwestern Medical Center    
Marios Sotiropoulos, BSc
University of Manchester   
Nicholas Henthorn, MSc
University of Manchester, Paterson Institute    
Michael Dingfelder, PhD
   East Carolina University 
PRESIDENTIAL SYMPOSIUM: Future radiobiology for advanced radiotherapies

Michael Baumann, MD, PhD
German Cancer Research Center
Dorthe Schaue, PhD
UCLA Health

Marco Durante, PhD
Trento Institute for Fundamentals
Physics Applications
Soren Bentzen, PhD, DMSc
University of Maryland
School of Medicine


Jan Schuemann, PhD
Dr. Schuemann is a radiation bio-physicist specializing in Monte Carlo (MC) simulation research for proton therapy and radiobiology. After spending 10 years in experimental high-energy particle physics and neutrino physics in Germany, Taiwan and Japan, he transitioned to medical physics as a post-doctorate in 2010 joining the team at the Massachusetts General Hospital/Harvard Medical School in Boston. Two years later, he joined the research team as Assistant Radiation Bio-Physicist at MGH and Instructor at HMS. In 2015, he started his current appointment as Assistant Professor of Radiation Oncology at MGH/HMS and Head of the Multi Scale MC Modeling Lab.

His research focuses on improving clinical treatment through the use of MC methods at multiple scales. At the macroscopic scale, he applies MC simulations to improve the accuracy of clinical dose and RBE distributions in patients. At the nanometer scale, he studies the biological effects of radiation on cell and sub-cellular components to better understand the underlying mechanisms of radiation effects with the goal to develop new ideas such as nanoparticle enhancement to improve radiation therapy outcome.

Gianluca Lattanzi, PhD
University of Trento
Walter Tinganelli, PhD
Trento Institute for Fundamentals
Physics Applications
David Brenner, PhD, DSc
Columbia University Medical Center
Elaine Zeman, PhD
UNC School of Medicine
Gayle Woloschak, PhD
Northwestern University Feinberg
School of Medicine

PLENARY LECTURE: Radiation and immunotherapy

Sandra Demaria, MD
Sandra Demaria, MD, a native of Turin, Italy, obtained her MD from the University of Turin. She then moved to New York City for her postdoctoral training in immunology is a Damon Runyon-Walter Winchell Cancer Research Fund awardee, followed by a residency in anatomic pathology at New York University School of Medicine. She remained on the faculty at NYU School of Medicine, where she was an attending pathologist in the breast cancer service, an independent investigator and co-leader of the Cancer Immunology program of NYU Cancer Institute until 2015, raising to the rank of Professor.

She is currently Professor of Radiation Oncology and Pathology at Weill Cornell Medicine Medical College where she leads a NIH-funded laboratory. Dr. Demaria is internationally known for her studies demonstrating the synergy of local radiation therapy with different immunotherapeutic agents in pre-clinical models of cancer. She was the first to show that radiotherapy can convert breast tumors unresponsive to immune checkpoint inhibitors into responsive ones. She has been working in partnership with Dr. Silvia Formenti for the past decade to develop a novel treatment paradigm exploiting the immune adjuvant effects of radiotherapy and translate the pre-clinical findings to the clinic.

Dr. Demaria's current work is aimed at identifying the molecular mechanisms that regulate ionizing radiation’s ability to generate an in situ tumor vaccine in preclinical tumor models as well as cancer patients treated in clinical trials testing various
combinations of radiation and immunotherapy. As a breast cancer pathologist Dr. Demaria has also studied the immunological microenvironment of breast cancer in patients, and therapeutic strategies to modulate the immune infiltrate in preclinical breast cancer models. She holds leadership positions in national professional societies, including the Society for Immunotherapy of Cancer (SITC) where she currently serves on the Board, and is a member of the Steering Committee of AACR Cancer Immunology Working Group. She is also an elected member of the European Academy for Tumor Immunology (EATI), and serves in the editorial board of several journals, including
Radiation Research, The Journal of Immunology, Clinical Cancer Research, and Journal for ImmunoTherapy of Cancer.

SYMPOSIUM 16: Radiation biology of model organisms: flies, worms, and fish
Don Fox, PhD
Duke School of Medicine
Annika Wylie, 
   UT Southwestern Medical Center
Ding Xue, PhD
University of Colorado- Boulder 
William Dynan, PhD
Emory University
SYMPOSIUM 17: DNA damage response and DNA repair
Maria Jasin, PhD
Memorial Sloan Kettering Cancer Center
Gaorav Gupta, PhD
University of North Carolina - Chapel Hill   
 Fen Xia, PhD
University of Arkansas for Medical Sciences    
Thomas Helleday, PhD
Karolinska Institutet
Sandeep Burma, PhD
 UT Southwestern Medical Center   
SYMPOSIUM 18: Co-sponsored by ASTRO: Clinical trials of radiation therapy and immunotherapy 
Jim Welsh, MD
MD Anderson Cancer Center
Kristina Young, MD, PhD
Oregon Health & Science University
Ann Klopp, MD, PhD
MD Anderson Cancer Center
Amit Maity, MD, PhD
Perelman School of Medicine,
University of Pennsylvania 

SYMPOSIUM 19: Radiomics, radiogenomics and artificial intelligence
Barry Rosenstein, MD, PhD 
NYU School of Medicine
Xiangfei Liu, PhD
University of Florida
Jacob Wynne, BS
  Emory University School of Medicine 
 Javier Torres-Roca, MD 
Moffitt Cancer Center
Paul Shofield
   University of Cambridge 
SYMPOSIUM 20: Medical countermeasures of radiation (mitigators)

John Chute, MD
UCLA Health
Deborah Bunin, PhD
 SRI International   
Maria Moroni, PhD
   Armed Forces Radiobiology Research Institute, USUHS 
Christie Orschell, PhD
Indiana University School of Medicine

Jae Ho Kim, MD
   Henry Ford Hospital 

Christopher Bakkenist, PhD
University of Pittsburgh
Medical Center

Piero Fossati, PhD
Claudia Wiese, PhD
Colorado State University

David Yu MD, PhD
Emory University
School of Medicine
Polly Chang, PhD
SRI International
James Lederer, PhD
Harvard Medical School 

PLENARY LECTURE: Biologically motivated treatment planning in proton therapy

Harald Paganetti, PhD
Director of Physics Research, Professor Massachusetts General Hospital
Harald Paganetti, PhD, is the Director of Physics Research at the Department of Radiation Oncology at Massachusetts General Hospital and a Professor of Radiation Oncology at Harvard Medical School. He received his PhD in experimental nuclear physics in 1992 from the Rheinische-Friedrich-Wilhelms University in Bonn, Germany, and has been working in radiation therapy research on experimental as well as theoretical aspects since 1994.

He is internationally recognized as an authority on proton therapy and specifically on Monte-Carlo simulations of dose and biological effects, the latter including modeling of clinical relative biological effectiveness as well as late effects. He has authored and co-authored more than 120 peer-reviewed publications and has edited a book on Proton Therapy Physics. For his research leadership he received the 2013 A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School. Dr. Paganetti has been awarded numerous research grants from the National Cancer Institute.

He serves on the editorial boards for the International Journal of Radiation Oncology, Biology, Physics as well as Technology in Cancer Research and Treatment. He is a member of numerous task groups and committees for various associations such as the American Association of Physicists in Medicine. Notably he is a member of the Radiation Physics Committee of the American Society for Therapeutic Radiology and Oncology. From 2009 to 2012 he was the Science Chair of the International Organization for Medical Physics. He is also a member of the Radiation Therapeutics and Biology Study Section at the National Cancer Institute.

SYMPOSIUM 21: Stem cells and radiation toxicity
Isabelle Lombaert, PhD
University of Michigan 
Quynh-Thu Le, MD
Stanford University
Benjamin Frisch, PhD
   University of Rochester
Jos Philipp, MS
   Helmholtz Muenchen Zentrum Institute of Radiation Biology
Alexandre Ribault, Phd
   Institute for Radiological Protection and Nuclear Safety (IRSN) 
SYMPOSIUM 22: Radiation Chemistry
Sylwia Ptasinska, PhD
University of Notre Dame 
Ian Carmichael, PhD
Notre Dame Radiation Laboratory
Mohamad Al-Sheikhly, PhD
University of Maryland
Eugene Surdutovich, PhD
Oakland University 
SYMPOSIUM 23: Radiation modifiers (protectors and sensitizers)
Meredith Morgan, PhD
University of Michigan
Terence Williams, PhD
The Ohio State University    
Sunil Advani, BS
University of California San Diego 
Ranjit Bindra, MD, PhD
Yale University School of Medicine 
Sudip Banerjee, PhD
UAMS - College of Pharmacy  
SYMPOSIUM 24: Proton and carbon ion radiotherapy
Thomas DeLaney, MD
Harvard Medical School
Waleed Gaber, PhD
Baylor College Of Medicine    
Piero Fossati, PhD
Anne-Sophie Wozny, Phd
Cellar and Molecular Radiobiology Laboratory   
Brock Sishc, PhD
University Of Texas Southwestern Medical Center    
SYMPOSIUM 25: Small animal irradiation

Phuoc Tran, MD, PhD
Johns Hopkins Medicine
Xiangkun Xu
   Johns Hopkins University
Vidya Kumar, PhD
  Armed Forces Radiobiology Research Institute  
Katia Parodi, PhD
LMU Munich
Munjal Acharya, PhD
University of California Irvine    

PAINTER DEBATE: This house believes that the biological mechanisms that underlie cancer development are sufficient to dismiss linear-no-threshold (LNT) modeling of cancer risk

Mary Helen Barcellos-Hoff, PhD
UCSF School of Medicine
 Francis A. Cucinotta, PhD
University of Nevada, Las Vegas


Amrita Cheema, PhD
Amrita Cheema, PhD, is a professor of Oncology and Biochemistry at Georgetown University Medical Center. She also co-directs the Waters Center of Innovation in Metabolomics at GUMC. Her extramurally funded research program is focused on delineating small molecule biomarkers that are predictive of exposure to ionizing radiation as well for adverse outcomes of radiotherapy. Her laboratory has also developed several tools and workflows for furthering metabolomics based molecular phenotyping for clinical and translational research. Amrita’s work has been documented in more than 40 peer reviewed publications and 5 biomarker patents.

PRESIDENTIAL SYMPOSIUM 2: p53 in radiation response and tumor suppression

Michael Kastan, MD, PhD
Duke Cancer Institute
Allan Balmain BSc, PhD
UCSF School of Medicine
Laura Attardi, PhD
Stanford Medicine
Andrei Gudkov, PhD, DSci
Roswell Park Comprehensive
Cancer Center

380 Ice Center Lane, Suite C | Bozeman, MT 59718 | 1.877.216.1919
Member & Exhibitor Services: Audrey Rinehart |
1.877.216.1919  |